Showing 6861-6870 of 7932 results for "".
- FDA Greenlights Restylane Lyft for Hand Rejuvenationhttps://practicaldermatology.com/news/fda-greenlights-restylane-lyft-for-hand-rejuvenation/2457757/The US Food and Drug Administration has approved Restylane Lyft for use on the dorsal hands of people older than 21, making it the first hyaluronic acid (HA) injectable gel approved for this use. Radiesse (Calcium Hydroxylapatite) is also approved for the correction of lost
- FDA Frowns on Evolus' Botox Rivalhttps://practicaldermatology.com/news/fda-frowns-on-evolus-botox-rival/2457763/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- National Psoriasis Foundation Honors Dr. Jerry Bagel with Excellence in Leadership Awardhttps://practicaldermatology.com/news/national-psoriasis-foundation-honors-dr-jerry-bagel-with-excellence-in-leadership-award/2457766/Jerry Bagel, MD, an internationally recognized expert in the treatment of psoriasis and founder of Windsor Dermatology and Psoriasis Treatment Center of Central New Jersey, will receive the Excellence in Leadership Award from the National Psoriasis Foundation (NPF) next month. For more th
- Skin Cancer Foundation Hits the Roadhttps://practicaldermatology.com/news/skin-cancer-foundation-hits-the-road/2457771/The Skin Cancer Foundation kicks off the second year of its mobile education and screeing program called Destination: Healthy Skin. Starting Tuesday, May 15, in New York City, the tour will stop in 15 cities ov
- Allergan Appoints Carrie Strom as Senior Vice President, U.S. Medical Aestheticshttps://practicaldermatology.com/news/allergan-appoints-carrie-strom-as-senior-vice-president-us-medical-aesthetics/2457776/Carrie Strom is Allergan’s new Senior Vice President, U.S. Medical Aesthetics, a portfolio of brands including BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® Collection of Fillers, Natrelle® col
- Study Seeks to Harness the Power of Probiotics to Treat Eczemahttps://practicaldermatology.com/news/study-seeks-to-harness-the-power-of-probiotics-to-treat-eczema/2457778/A new clinical trial is investigating whether beneficial bacteria can help treat eczema by restoring the natural microbial balance of healthy skin. "There are over 1,000 species of bacteria that all live in balance on healthy skin, some that even produce natural antibiotics. However,
- Daily Aspirin Linked to Higher Melanoma Risk in Menhttps://practicaldermatology.com/news/daily-aspirin-linked-to-higher-melanoma-risk-in-men/2457779/Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who don’t, reports a new Northwestern Medicine study. Women, however, do not have an increased risk in this large patient population, the study showed. The study collected medical record
- DermTech Partners with Melanoma Research Foundation to Support Miles for Melanomahttps://practicaldermatology.com/news/dermtech-partners-with-melanoma-research-foundation-to-support-miles-for-melanoma/2457781/DermTech, Inc. is partnering with the Melanoma Research Foundation in support of five Miles for Melanoma Runs/Walks held throughout the US, kicking off this month during Melanoma Awareness
- Sensus Appoints Rita Gable as VP of Sales, Oncologyhttps://practicaldermatology.com/news/sensus-appoints-rita-gable-as-vp-of-sales-oncology/2457783/Sensus Healthcare, Inc. has appointed Rita Gable as Vice President of Sales – Oncology. Ms. Gable, who will report to Joe Sardano, Sensus CEO, has 15 years of sales e
- FDA Approves Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanomahttps://practicaldermatology.com/news/fda-approves-tafinlar-mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma/2457786/The FDA has approved Novartis' Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. The FDA